Drug companies were a more important source of revenue for Lonza in 2015 than in previous years with four of its five biggest spending customers coming from the pharmaceutical sector.
Biopharma outsourcing growth has helped to boost the bottom line of Lonza, the world’s largest manufacturer of drug ingredients, though a topsy-turvy Swiss franc has caused the company to hold off on making any projections for 2015.
Roche will cut 4,800 jobs worldwide over the next two years as part of a restructuring program designed to slash $2.4bn Swiss francs ($2.4bn) from annual costs.
Shareholders at Swiss pharmaceutical company Roche welcomed the
start of a new era as the company summarised recent events,
including the divestment of the vitamins business, at its annual
general meeting yesterday.
